Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 2/2019

01-02-2019 | Original Article

Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature

Authors: Claire Briet, Mirela Diana Ilie, Emmanuelle Kuhn, Luigi Maione, Sylvie Brailly-Tabard, Sylvie Salenave, Bertrand Cariou, Philippe Chanson

Published in: Endocrine | Issue 2/2019

Login to get access

Summary

Context

Untreated acromegaly is associated with increased morbidity and mortality due to malignant, cardiovascular, and cerebrovascular disorders. Effective treatment of acromegaly reduces excess mortality, but its impact on cardiovascular risk factors and metabolic parameters are poorly documented.

Aim

We analyzed changes in cardiovascular risk factors and metabolic parameters in patients receiving various treatment modalities.

Patients and methods

We retrospectively studied 96 patients with acromegaly, both at diagnosis and after IGF-I normalization following surgery alone (n = 51) or medical therapy with first generation somatostatin analogues (SSA, n = 23), or pegvisomant (n = 22). Duration of follow-up was 77 (42–161) months, 75 (42–112) months, and 62 (31–93) months, in patients treated with surgery alone, SSA, and pegvisomant, respectively. In all the cases except four, patients treated medically had underwent previous unsuccessful surgery.

Results

IGF-I normalization was associated with increased body weight, decreased systolic blood pressure (SBP) in hypertensive patients, decreased fasting plasma glucose (FPG) and HOMA-IR and HOMA-B levels, increased HDL cholesterol (HDLc); whereas, LDL cholesterol (LDLc) was not significantly different. Plasma PCSK9 levels were unchanged in patients with available values. Cardiovascular and metabolic changes varied with the treatment modality: surgery, but not pegvisomant, had a beneficial effect on SBP; FPG decreased after surgery but increased after SSA; the decline in HOMA-IR was only significant after surgery; pegvisomant significantly increased LDLc and total cholesterol; whereas SA increased HDLc and had no effect on LDLc levels.

Conclusion

Treatments used to normalize IGF-I levels in patients with acromegaly could have differential effects on cardiovascular risk factors and metabolic parameters.
Appendix
Available only for authorised users
Literature
1.
2.
3.
A. Colao, D. Ferone, P. Marzullo, G. Lombardi, Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr. Rev. 25(1), 102–152 (2004)CrossRefPubMed
4.
M. Sherlock, J. Ayuk, J.W. Tomlinson, A.A. Toogood, A. Aragon-Alonso, M.C. Sheppard, A.S. Bates, P.M. Stewart, Mortality in patients with pituitary disease. Endocr. Rev. 31(3), 301–342 (2010)CrossRefPubMed
5.
C. Berg, S. Petersenn, H. Lahner, B.L. Herrmann, M. Buchfelder, M. Droste, G.K. Stalla, C.J. Strasburger, U. Roggenbuck, N. Lehmann, S. Moebus, K.H. Jockel, S. Mohlenkamp, R. Erbel, B. Saller, K. Mann, Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J. Clin. Endocrinol. Metab. 95(8), 3648–3656 (2010)CrossRefPubMed
6.
L. Boero, M. Manavela, L. Gomez Rosso, C. Insua, V. Berardi, M.C. Fornari, F. Brites, Alterations in biomarkers of cardiovascular disease (CVD) in active acromegaly. Clin. Endocrinol. 70(1), 88–95 (2009)CrossRef
7.
S. Cannavo, B. Almoto, G. Cavalli, S. Squadrito, G. Romanello, M.T. Vigo, F. Fiumara, S. Benvenga, F. Trimarchi, Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography. J. Clin. Endocrinol. Metab. 91(10), 3766–3772 (2006)CrossRefPubMed
8.
B.L. Herrmann, M. Severing, A. Schmermund, C. Berg, T. Budde, R. Erbel, K. Mann, Impact of disease duration on coronary calcification in patients with acromegaly. Exp. Clin. Endocrinol. Diabetes 117(8), 417–422 (2009)CrossRefPubMed
9.
F. Bogazzi, L. Battolla, C. Spinelli, G. Rossi, S. Gavioli, V. Di Bello, C. Cosci, C. Sardella, D. Volterrani, E. Talini, P. Pepe, F. Falaschi, G. Mariani, E. Martino, Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J. Clin. Endocrinol. Metab. 92(11), 4271–4277 (2007)CrossRefPubMed
10.
M. Bex, R. Abs, G. T’Sjoen, J. Mockel, B. Velkeniers, K. Muermans, D. Maiter, AcroBel the Belgian registry on acromegaly: a survey of the ‘real-life’ outcome in 418 acromegalic subjects. Eur. J. Endocrinol. 157(4), 399–409 (2007)CrossRefPubMed
11.
H. Akutsu, J. Kreutzer, G. Wasmeier, D. Ropers, C. Rost, M. Mohlig, H. Wallaschofski, M. Buchfelder, C. Schofl, Acromegaly per se does not increase the risk for coronary artery disease. Eur. J. Endocrinol. 162(5), 879–886 (2010)CrossRefPubMed
12.
M. Ragonese, A. Alibrandi, G. Di Bella, I. Salamone, S. Puglisi, O.R. Cotta, M.L. Torre, F. Ferrau, R.M. Ruggeri, F. Trimarchi, S. Cannavo, Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction. Endocrine 47(1), 206–212 (2014)PubMed
13.
M. Fleseriu, Insight into cardiovascular risk factors in patients with acromegaly. Endocrine 47(1), 1–2 (2014)CrossRefPubMed
14.
M. Arosio, G. Reimondo, E. Malchiodi, P. Berchialla, A. Borraccino, L. De Marinis, R. Pivonello, S. Grottoli, M. Losa, S. Cannavo, F. Minuto, M. Montini, M. Bondanelli, E. De Menis, C. Martini, G. Angeletti, A. Velardo, A. Peri, M. Faustini-Fustini, P. Tita, F. Pigliaru, G. Borretta, C. Scaroni, N. Bazzoni, A. Bianchi, M. Appetecchia, F. Cavagnini, G. Lombardi, E. Ghigo, P. Beck-Peccoz, A. Colao, M. Terzolo, Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur. J. Endocrinol. 167(2), 189–198 (2012)CrossRefPubMed
15.
M. Mercado, B. Gonzalez, G. Vargas, C. Ramirez, A.L. de los Monteros, E. Sosa, P. Jervis, P. Roldan, V. Mendoza, B. Lopez-Felix, G. Guinto, Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J. Clin. Endocrinol. Metab. 99(12), 4438–4446 (2014)CrossRefPubMed
16.
O.M. Dekkers, N.R. Biermasz, A.M. Pereira, J.A. Romijn, J.P. Vandenbroucke, Mortality in acromegaly: a metaanalysis. J. Clin. Endocrinol. Metab. 93(1), 61–67 (2008)CrossRefPubMed
17.
I.M. Holdaway, M.J. Bolland, G.D. Gamble, A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur. J. Endocrinol. 159(2), 89–95 (2008)CrossRefPubMed
18.
A. Colao, Improvement of cardiac parameters in patients with acromegaly treated with medical therapies. Pituitary 15(1), 50–58 (2012)CrossRefPubMed
19.
T.J. Reid, Z. Jin, W. Shen, C.M. Reyes-Vidal, J.C. Fernandez, J.N. Bruce, J. Kostadinov, K.D. Post, P.U. Freda, IGF-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivity, markers of cardiovascular risk and body composition. Pituitary 18(6), 808–819 (2015)CrossRefPubMedPubMedCentral
20.
J. Verhelst, B. Velkeniers, D. Maiter, P. Haentjens, G. T’Sjoen, E. Rietzschel, B. Corvilain, P. Abrams, F. Nobels, R. Abs, M. Bex, Active acromegaly is associated with decreased hs-CRP and NT-proBNP serum levels: insights from the Belgian registry of acromegaly. Eur. J. Endocrinol. 168(2), 177–184 (2013)CrossRefPubMed
21.
R. Lindberg-Larsen, N. Moller, O. Schmitz, S. Nielsen, M. Andersen, H. Orskov, J.O. Jorgensen, The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. J. Clin. Endocrinol. Metab. 92(5), 1724–1728 (2007)CrossRefPubMed
22.
G. Sesmilo, W.P. Fairfield, L. Katznelson, K. Pulaski, P.U. Freda, V. Bonert, E. Dimaraki, S. Stavrou, M.L. Vance, D. Hayden, A. Klibanski, Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J. Clin. Endocrinol. Metab. 87(4), 1692–1699 (2002)CrossRefPubMed
23.
U. Plockinger, T. Reuter, Pegvisomant increases intra-abdominal fat in patients with acromegaly: a pilot study. Eur. J. Endocrinol. 158(4), 467–471 (2008)CrossRefPubMed
24.
C. Parkinson, W.M. Drake, G. Wieringa, A.P. Yates, G.M. Besser, P.J. Trainer, Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly. Clin. Endocrinol. 56(3), 303–311 (2002)CrossRef
25.
R.A. James, N. Moller, S. Chatterjee, M. White, P. Kendall-Taylor, Carbohydrate tolerance and serum lipids in acromegaly before and during treatment with high dose octreotide. Diabet. Med. 8(6), 517–523 (1991)CrossRefPubMed
26.
K.S. Lam, R.W. Pang, E.D. Janus, A.W. Kung, C.C. Wang, Serum apolipoprotein(a) correlates with growth hormone levels in Chinese patients with acromegaly. Atherosclerosis 104(1-2), 183–188 (1993)CrossRefPubMed
27.
K.C. Tan, R.W. Pang, S.C. Tiu, K.S. Lam, Effects of treatment with Sandostatin LAR on small dense LDL and remnant-like lipoproteins in patients with acromegaly. Clin. Endocrinol. 59(5), 558–564 (2003)CrossRef
28.
A. Colao, P. Marzullo, G. Lombardi, Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. Eur. J. Endocrinol. 146(3), 303–309 (2002)CrossRefPubMed
29.
C. Reyes-Vidal, J.C. Fernandez, J.N. Bruce, C. Crisman, I.M. Conwell, J. Kostadinov, E.B. Geer, K.D. Post, P.U. Freda, Prospective study of surgical treatment of acromegaly: effects on ghrelin, weight, adiposity, and markers of CV risk. J. Clin. Endocrinol. Metab. 99(11), 4124–4132 (2014)CrossRefPubMedPubMedCentral
30.
O. Topaloglu, M. Sayki Arslan, O. Turak, Z. Ginis, M. Sahin, M. Cebeci, B. Ucan, E. Cakir, B. Karbek, M. Ozbek, E. Cakal, T. Delibasi, Three noninvasive methods in the evaluation of subclinical cardiovascular disease in patients with acromegaly: epicardial fat thickness, aortic stiffness and serum cell adhesion molecules. Clin. Endocrinol. 80(5), 726–734 (2014)CrossRef
31.
C. Ozkan, A.E. Altinova, E.T. Cerit, C. Yayla, A. Sahinarslan, D. Sahin, A.S. Dincel, F.B. Toruner, M. Akturk, M. Arslan, Markers of early atherosclerosis, oxidative stress and inflammation in patients with acromegaly. Pituitary 18(5), 621–629 (2015)CrossRefPubMed
32.
M. Kaluzny, M. Bolanowski, J. Daroszewski, A. Szuba, The role of fibrinogen and CRP in cardiovascular risk in patients with acromegaly. Endokrynol. Pol. 61(1), 83–88 (2010)PubMed
33.
H. Sakai, K. Tsuchiya, C. Nakayama, F. Iwashima, H. Izumiyama, M. Doi, T. Yoshimoto, M. Tsujino, S. Yamada, Y. Hirata, Improvement of endothelial dysfunction in acromegaly after transsphenoidal surgery. Endocr. J. 55(5), 853–859 (2008)CrossRefPubMed
34.
Z. Hekimsoy, B. Ozmen, S. Ulusoy, Homocysteine levels in acromegaly patients. Neuro. Endocrinol. Lett. 26(6), 811–814 (2005)PubMed
35.
A. Colao, A. Cuocolo, P. Marzullo, E. Nicolai, D. Ferone, A.M. Della Morte, R. Pivonello, M. Salvatore, G. Lombardi, Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. J. Clin. Endocrinol. Metab. 86(4), 1551–1557 (2001)PubMed
36.
M. Arosio, G. Sartore, C.M. Rossi, G. Casati, G. Faglia, E. Manzato, LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Italian Multicenter Octreotide Study Group. Atherosclerosis 151(2), 551–557 (2000)CrossRefPubMed
37.
R.S. Auriemma, R. Pivonello, M.C. De Martino, G. Cudemo, L.F. Grasso, M. Galdiero, Y. Perone, A. Colao, Treatment with GH receptor antagonist in acromegaly: effect on cardiac arrhythmias. Eur. J. Endocrinol. 168(1), 15–22 (2013)CrossRefPubMed
38.
D. Fedrizzi, T.C. Rodrigues, F. Costenaro, R. Scalco, M.A. Czepielewski, Hypertension-related factors in patients with active and inactive acromegaly. Arq. Bras. Endocrinol. Metabol. 55(7), 468–474 (2011)CrossRefPubMed
39.
L. Vilar, L.A. Naves, S.S. Costa, L.F. Abdalla, C.E. Coelho, L.A. Casulari, Increase of classic and nonclassic cardiovascular risk factors in patients with acromegaly. Endocr. Pract. 13(4), 363–372 (2007)CrossRefPubMed
40.
G.F. Maldonado Castro, H.F. Escobar-Morreale, H. Ortega, D. Gomez-Coronado, J.A. Balsa Barro, C. Varela, M.A. Lasuncion, Effects of normalization of GH hypersecretion on lipoprotein(a) and other lipoprotein serum levels in acromegaly. Clin. Endocrinol. 53(3), 313–319 (2000)CrossRef
41.
J. Oscarsson, O. Wiklund, K.E. Jakobsson, B. Petruson, B.A. Bengtsson, Serum lipoproteins in acromegaly before and 6-15 months after transsphenoidal adenomectomy. Clin. Endocrinol. 41(5), 603–608 (1994)CrossRef
42.
S.S. Damjanovic, A.N. Neskovic, M.S. Petakov, V. Popovic, D. Macut, P. Vukojevic, M.M. Joksimovic, Clinical indicators of biochemical remission in acromegaly: Does incomplete disease control always mean therapeutic failure? Clin. Endocrinol. 62(4), 410–417 (2005)CrossRef
43.
B.L. Herrmann, C. Bruch, B. Saller, T. Bartel, S. Ferdin, R. Erbel, K. Mann, Acromegaly: evidence for a direct relation between disease activity and cardiac dysfunction in patients without ventricular hypertrophy. Clin. Endocrinol. 56(5), 595–602 (2002)CrossRef
44.
C.L. Ronchi, V. Varca, P. Beck-Peccoz, E. Orsi, F. Donadio, A. Baccarelli, C. Giavoli, E. Ferrante, A. Lania, A. Spada, M. Arosio, Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J. Clin. Endocrinol. Metab. 91(1), 121–128 (2006)CrossRefPubMed
45.
E. Kuhn, L. Maione, A. Bouchachi, M. Roziere, S. Salenave, S. Brailly-Tabard, J. Young, P. Kamenicky, P. Assayag, P. Chanson, Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study. Eur. J. Endocrinol. 173(5), 693–702 (2015)CrossRefPubMedPubMedCentral
46.
N.C. Olarescu, A. Heck, K. Godang, T. Ueland, J. Bollerslev, The metabolic risk in patients newly diagnosed with acromegaly is related to fat distribution and circulating adipokines and improves after treatment. Neuroendocrinology 103(3–4), 197–206 (2016)CrossRefPubMed
47.
E. Lin, T.L. Wexler, L. Nachtigall, N. Tritos, B. Swearingen, L. Hemphill, J. Loeffler, B.M. Biller, A. Klibanski, K.K. Miller, Effects of growth hormone deficiency on body composition and biomarkers of cardiovascular risk after definitive therapy for acromegaly. Clin. Endocrinol. 77(3), 430–438 (2012)CrossRef
48.
C. Dimopoulou, C. Sievers, H.U. Wittchen, L. Pieper, J. Klotsche, J. Roemmler, J. Schopohl, H.J. Schneider, G.K. Stalla, Adverse anthropometric risk profile in biochemically controlled acromegalic patients: comparison with an age- and gender-matched primary care population. Pituitary 13(3), 207–214 (2010)CrossRefPubMedPubMedCentral
49.
J.C. Smith, H. Lane, N. Davies, L.M. Evans, J. Cockcroft, M.F. Scanlon, J.S. Davies, The effects of depot long-acting somatostatin analog on central aortic pressure and arterial stiffness in acromegaly. J. Clin. Endocrinol. Metab. 88(6), 2556–2561 (2003)CrossRefPubMed
50.
A. Colao, R. Pivonello, R.S. Auriemma, M.C. De Martino, M. Bidlingmaier, F. Briganti, F. Tortora, P. Burman, I.A. Kourides, C.J. Strasburger, G. Lombardi, Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur. J. Endocrinol. 154(3), 467–477 (2006)CrossRefPubMed
51.
C. Yayla, U. Canpolat, A. Sahinarslan, C. Ozkan, A. Eroglu Altinova, K. Gayretli Yayla, M.K. Akboga, A. Eyiol, B. Boyaci, The Assessment Of Atrial Electromechanical Delay In Patients With Acromegaly. Can. J. Cardiol. 31(8), 1012–1018 (2015)CrossRefPubMed
52.
J.D. Horton, J.C. Cohen, H.H. Hobbs, PCSK9: a convertase that coordinates LDL catabolism. J. Lipid Res. 50, Suppl, S172–177 (2009)CrossRefPubMed
53.
C. Galman, M. Matasconi, L. Persson, P. Parini, B. Angelin, M. Rudling, Age-induced hypercholesterolemia in the rat relates to reduced elimination but not increased intestinal absorption of cholesterol. Am. J. Physiol. Endocrinol. Metab. 293(3), E737–742 (2007)CrossRefPubMed
54.
L. Persson, G. Cao, L. Stahle, B.G. Sjoberg, J.S. Troutt, R.J. Konrad, C. Galman, H. Wallen, M. Eriksson, I. Hafstrom, S. Lind, M. Dahlin, P. Amark, B. Angelin, M. Rudling, Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. Arterioscler. Thromb. Vasc. Biol. 30(12), 2666–2672 (2010)CrossRefPubMed
55.
P. Chanson, S. Salenave, P. Kamenicky, L. Cazabat, J. Young, Pituitary tumours: acromegaly. Best Pract. Res. Clin. Endocrinol. Metab. 23(5), 555–574 (2009)CrossRefPubMed
56.
A. Giustina, A. Barkan, F.F. Casanueva, F. Cavagnini, L. Frohman, K. Ho, J. Veldhuis, J. Wass, K. Von Werder, S. Melmed, Criteria for cure of acromegaly: a consensus statement. J. Clin. Endocrinol. Metab. 85(2), 526–529 (2000)PubMed
57.
A. Giustina, P. Chanson, M.D. Bronstein, A. Klibanski, S. Lamberts, F.F. Casanueva, P. Trainer, E. Ghigo, K. Ho, S. Melmed, A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95(7), 3141–3148 (2010)CrossRefPubMed
58.
P. Kamenicky, C. Dos Santos, C. Espinosa, S. Salenave, F. Galland, Y. Le Bouc, P. Maison, P. Bougneres, P. Chanson, D3 GH receptor polymorphism is not associated with IGF1 levels in untreated acromegaly. Eur. J. Endocrinol. 161(2), 231–235 (2009)CrossRefPubMed
59.
O. Alexopoulou, M. Bex, P. Kamenicky, A.B. Mvoula, P. Chanson, D. Maiter, Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary 17(1), 81–89 (2014)CrossRefPubMed
60.
D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7), 412–419 (1985)CrossRef
61.
P. Costet, M.M. Hoffmann, B. Cariou, B. Guyomarc’h Delasalle, T. Konrad, K. Winkler, Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis 212(1), 246–251 (2010)CrossRefPubMed
62.
B.A. Bengtsson, R.J. Brummer, S. Eden, I. Bosaeus, Body composition in acromegaly. Clin. Endocrinol. 30(2), 121–130 (1989)CrossRef
63.
A.J. O’Sullivan, J.J. Kelly, D.M. Hoffman, J. Freund, K.K. Ho, Body composition and energy expenditure in acromegaly. J. Clin. Endocrinol. Metab. 78(2), 381–386 (1994)PubMed
64.
P.U. Freda, W. Shen, S.B. Heymsfield, C.M. Reyes-Vidal, E.B. Geer, J.N. Bruce, D. Gallagher, Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly. J. Clin. Endocrinol. Metab. 93(6), 2334–2343 (2008)CrossRefPubMedPubMedCentral
65.
66.
B.A. Bengtsson, R.J. Brummer, S. Eden, I. Bosaeus, G. Lindstedt, Body composition in acromegaly: the effect of treatment. Clin. Endocrinol. 31(4), 481–490 (1989)CrossRef
67.
B.A. Bengtsson, R.J. Brummer, I. Bosaeus, Growth hormone and body composition. Horm. Res. 33 Suppl 4, 19–24 (1990)CrossRefPubMed
68.
K. Landin, B. Petruson, K.E. Jakobsson, B.A. Bengtsson, Skeletal muscle sodium and potassium changes after successful surgery in acromegaly: relation to body composition, blood glucose, plasma insulin and blood pressure. Acta Endocrinol. 128(5), 418–422 (1993)CrossRefPubMed
69.
A. Tominaga, K. Arita, K. Kurisu, T. Uozumi, K. Migita, K. Eguchi, K. IIda, H. Kawamoto, T. Mizoue, Effects of successful adenomectomy on body composition in acromegaly. Endocr. J. 45(3), 335–342 (1998)CrossRefPubMed
70.
71.
R.J. Brummer, L. Lonn, H. Kvist, U. Grangard, B.A. Bengtsson, L. Sjostrom, Adipose tissue and muscle volume determination by computed tomography in acromegaly, before and 1 year after adenomectomy. Eur. J. Clin. Invest. 23(4), 199–205 (1993)CrossRefPubMed
72.
N. Sucunza, M.J. Barahona, E. Resmini, J.M. Fernandez-Real, J. Farrerons, P. Lluch, T. Puig, A.M. Wagner, W. Ricart, S.M. Webb, Gender dimorphism in body composition abnormalities in acromegaly: males are more affected than females. Eur. J. Endocrinol. 159(6), 773–779 (2008). https://​doi.​org/​10.​1530/​EJE-08-0449 CrossRefPubMed
73.
H. Rau, H. Fischer, K. Schmidt, B. Lembcke, P.H. Althoff, Effect of bromocriptine withdrawal in acromegaly on body composition as assessed by bioelectrical impedance analysis. Acta Endocrinol. 125(3), 273–279 (1991)CrossRefPubMed
74.
M.A. Bredella, M. Schorr, L.E. Dichtel, A.V. Gerweck, B.J. Young, W.W. Woodmansee, B. Swearingen, K.K. Miller, Body composition and ectopic lipid changes with biochemical control of acromegaly. J. Clin. Endocrinol. Metab. 102(11), 4218–4225 (2017)CrossRefPubMedPubMedCentral
75.
N.C. Olarescu, T. Ueland, K. Godang, R. Lindberg-Larsen, J.O. Jorgensen, J. Bollerslev, Inflammatory adipokines contribute to insulin resistance in active acromegaly and respond differently to different treatment modalities. Eur. J. Endocrinol. 170(1), 39–48 (2014)CrossRefPubMed
76.
P. Kamenicky, A. Blanchard, M. Frank, S. Salenave, A. Letierce, M. Azizi, M. Lombes, P. Chanson, Body fluid expansion in acromegaly is related to enhanced epithelial sodium channel (ENaC) activity. J. Clin. Endocrinol. Metab. 96(7), 2127–2135 (2011)CrossRefPubMed
77.
M.L. Jaffrain-Rea, G. Minniti, C. Moroni, V. Esposito, E. Ferretti, A. Santoro, T. Infusino, G. Tamburrano, G. Cantore, R. Cassone, Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly. Eur. J. Endocrinol. 148(2), 193–201 (2003)CrossRefPubMed
78.
M. Yonenaga, S. Fujio, M. Habu, H. Arimura, T. Hiwatari, S. Tanaka, Y. Kinoshita, H. Hosoyama, H. Hirano, K. Arita, Postoperative changes in metabolic parameters of patients with surgically controlled acromegaly: assessment of new stringent cure criteria. Neurol. Med. Chir. 58(4), 147–155 (2018)CrossRef
79.
C.B. Vianna, M.L. Vieira, C. Mady, B. Liberman, A.E. Durazzo, M. Knoepfelmacher, L.R. Salgado, J.A. Ramires, Treatment of acromegaly improves myocardial abnormalities. Am. Heart J. 143(5), 873–876 (2002)CrossRefPubMed
80.
A. Colao, M. Terzolo, M. Bondanelli, M. Galderisi, G. Vitale, G. Reimondo, M.R. Ambrosio, R. Pivonello, G. Lombardi, A. Angeli, E.C. degli Uberti, GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment. Clin. Endocrinol. 69(4), 613–620 (2008)CrossRef
81.
M.J. Lim, A.L. Barkan, A.J. Buda, Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion. Ann. Intern. Med. 117(9), 719–726 (1992)CrossRefPubMed
82.
F. Bogazzi, M. Lombardi, E. Strata, G. Aquaro, M. Lombardi, C. Urbani, V. Di Bello, C. Cosci, C. Sardella, E. Talini, E. Martino, Effects of somatostatin analogues on acromegalic cardiomyopathy: results from a prospective study using cardiac magnetic resonance. J. Endocrinol. Invest. 33(2), 103–108 (2010)CrossRefPubMed
83.
T.L. Wexler, R. Durst, D. McCarty, M.H. Picard, L. Gunnell, Z. Omer, P. Fazeli, K.K. Miller, A. Klibanski, Growth hormone status predicts left ventricular mass in patients after cure of acromegaly. Growth Horm. IGF Res. 20(5), 333–337 (2010)CrossRefPubMedPubMedCentral
84.
C. Sardella, C. Urbani, M. Lombardi, A. Nuzzo, L. Manetti, I. Lupi, G. Rossi, S. Del Sarto, I. Scattina, V. Di Bello, E. Martino, F. Bogazzi, The beneficial effect of acromegaly control on blood pressure values in normotensive patients. Clin. Endocrinol. 81(4), 573–581 (2014)CrossRef
85.
R.S. Auriemma, L.F. Grasso, M. Galdiero, M. Galderisi, C. Pivonello, C. Simeoli, M.C. De Martino, R. Ferrigno, M. Negri, C. de Angelis, R. Pivonello, A. Colao, Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. Endocrine 55(3), 872–884 (2017)CrossRefPubMed
86.
A. Amado, F. Araujo, D. Carvalho, Cardiovascular risk factors in acromegaly: what’s the impact of disease control? Exp. Clin. Endocrinol. Diabetes 126, 505–512 (2018)CrossRefPubMed
87.
A. Colao, R. Pivonello, M. Galderisi, P. Cappabianca, R.S. Auriemma, M. Galdiero, L.M. Cavallo, F. Esposito, G. Lombardi, Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J. Clin. Endocrinol. Metab. 93(7), 2639–2646 (2008)CrossRefPubMed
88.
G. Minniti, C. Moroni, M.L. Jaffrain-Rea, V. Esposito, A. Santoro, C. Affricano, G. Cantore, G. Tamburrano, R. Cassone, Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients. Clin. Endocrinol. 55(3), 307–313 (2001)CrossRef
89.
A.E. Schutte, M. Volpe, G. Tocci, E. Conti, Revisiting the relationship between blood pressure and insulin-like growth factor-1. Hypertension 63(5), 1070–1077 (2014)CrossRefPubMed
90.
C. Berg, S. Petersenn, M. Walensi, S. Mohlenkamp, M. Bauer, N. Lehmann, U. Roggenbuck, S. Moebus, M. Broecker-Preuss, I.E. Sandalcioglu, D. Stolke, U. Sure, K.H. Joeckel, R. Erbel, D. Fuhrer, K. Mann, Investigative Group of the Heinz Nixdorf Recall, S.: cardiac risk in patients with treatment naive, first-line medically controlled and first-line surgically cured acromegaly in comparison to matched data from the general population. Exp. Clin. Endocrinol. Diabetes 121(2), 125–132 (2013)CrossRefPubMed
91.
G. Lombardi, A. Colao, P. Marzullo, B. Biondi, E. Palmieri, S. Fazio, Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study. J. Endocrinol. Invest. 25(11), 971–976 (2002)CrossRefPubMed
92.
A. Colao, L. Spinelli, A. Cuocolo, S. Spiezia, R. Pivonello, C. di Somma, D. Bonaduce, M. Salvatore, G. Lombardi, Cardiovascular consequences of early-onset growth hormone excess. J. Clin. Endocrinol. Metab. 87(7), 3097–3104 (2002)CrossRefPubMed
93.
R. Pivonello, M. Galderisi, R.S. Auriemma, M.C. De Martino, M. Galdiero, A. Ciccarelli, A. D’Errico, I. Kourides, P. Burman, G. Lombardi, A. Colao, Treatment with growth hormone receptor antagonist in acromegaly: Effect on cardiac structure and performance. J. Clin. Endocrinol. Metab. 92(2), 476–482 (2007)CrossRefPubMed
94.
R.S. Auriemma, R. Pivonello, M. Galdiero, M.C. De Martino, M. De Leo, G. Vitale, G. Lombardi, A. Colao, Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: a retrospective, comparative, head-to-head study. J. Endocrinol. Invest. 31(11), 956–965 (2008)CrossRefPubMed
95.
C. Jonas, D. Maiter, O. Alexopoulou, Evolution of glucose tolerance after treatment of acromegaly: a study in 57 patients. Horm. Metab. Res. 48(5), 299–305 (2016)CrossRefPubMed
96.
B. Biagetti, G. Obiols, S. Valladares, L. Arnez, B. Dalama, J. Mesa, [Abnormalities of carbohydrate metabolism in acromegaly]. Med Clin. 141(10), 442–446 (2013)CrossRef
97.
C. Ronchi, P. Epaminonda, V. Cappiello, P. Beck-Peccoz, M. Arosio, Effects of two different somatostatin analogs on glucose tolerance in acromegaly. J. Endocrinol. Invest. 25(6), 502–507 (2002)CrossRefPubMed
98.
C. Urbani, C. Sardella, A. Calevro, G. Rossi, I. Scattina, M. Lombardi, I. Lupi, L. Manetti, E. Martino, F. Bogazzi, Effects of medical therapies for acromegaly on glucose metabolism. Eur. J. Endocrinol. 169(1), 99–108 (2013)CrossRefPubMed
99.
R. Baldelli, C. Battista, F. Leonetti, M.R. Ghiggi, M.C. Ribaudo, A. Paoloni, E. D’Amico, E. Ferretti, R. Baratta, A. Liuzzi, V. Trischitta, G. Tamburrano, Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin. Endocrinol. 59(4), 492–499 (2003)CrossRef
100.
A.L. Barkan, P. Burman, D.R. Clemmons, W.M. Drake, R.F. Gagel, P.E. Harris, P.J. Trainer, A.J. van der Lely, M.L. Vance, Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J. Clin. Endocrinol. Metab. 90(10), 5684–5691 (2005)CrossRefPubMed
101.
W.M. Drake, S.V. Rowles, M.E. Roberts, F.K. Fode, G.M. Besser, J.P. Monson, P.J. Trainer, Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur. J. Endocrinol. 149(6), 521–527 (2003)CrossRefPubMed
102.
C. Parkinson, W.M. Drake, M.E. Roberts, K. Meeran, G.M. Besser, P.J. Trainer, A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. J. Clin. Endocrinol. Metab. 87(4), 1797–1804 (2002)CrossRefPubMed
103.
G. Mazziotti, I. Floriani, S. Bonadonna, V. Torri, P. Chanson, A. Giustina, Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J. Clin. Endocrinol. Metab. 94(5), 1500–1508 (2009)CrossRefPubMed
104.
C. Giordano, A. Ciresi, M.C. Amato, R. Pivonello, R.S. Auriemma, L.F. Grasso, A. Galluzzo, A. Colao, Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study. Pituitary 15(4), 539–551 (2012)CrossRefPubMed
105.
K. Mori, Y. Iwasaki, Y. Kawasaki-Ogita, S. Honjo, Y. Hamamoto, H. Tatsuoka, K. Fujimoto, H. Ikeda, Y. Wada, Y. Takahashi, J. Takahashi, H. Koshiyama, Improvement of insulin resistance following transsphenoidal surgery in patients with acromegaly: correlation with serum IGF-I levels. J. Endocrinol. Invest. 36(10), 853–859 (2013)PubMed
106.
A. Colao, C. Di Somma, T. Cascella, R. Pivonello, G. Vitale, L.F.S. Grasso, G. Lombardi, S. Savastano, Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects. Eur. J. Endocrinol. 159(4), 389–397 (2008)CrossRefPubMed
107.
A. Colao, S. Spiezia, G. Cerbone, R. Pivonello, P. Marzullo, D. Ferone, C. Di Somma, A.P. Assanti, G. Lombardi, Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. Clin. Endocrinol. (Oxf.). 54(4), 515–524 (2001)CrossRefPubMed
108.
C.M. Reyes-Vidal, H. Mojahed, W. Shen, Z. Jin, F. Arias-Mendoza, J.C. Fernandez, D. Gallagher, J.N. Bruce, K.D. Post, P.U. Freda, Adipose tissue redistribution and ectopic lipid deposition in active acromegaly and effects of surgical treatment. J. Clin. Endocrinol. Metab. 100(8), 2946–2955 (2015)CrossRefPubMedPubMedCentral
109.
S. Frara, F. Maffezzoni, G. Mazziotti, A. Giustina, Current and emerging aspects of diabetes mellitus in acromegaly. Trends Endocrinol. Metab. 27(7), 470–483 (2016)CrossRefPubMed
110.
C. Rochette, T. Graillon, F. Albarel, I. Morange, H. Dufour, T. Brue, F. Castinetti, Increased risk of persistent glucose disorders after control of acromegaly. J. Endocr. Soc. 1(12), 1531–1539 (2017)CrossRefPubMedPubMedCentral
111.
M. Rudling, P. Parini, B. Angelin, Effects of growth hormone on hepatic cholesterol metabolism. Lessons from studies in rats and humans. Growth Horm. IGF Res. 9(Suppl A), 1–7 (1999)CrossRefPubMed
112.
P.J. Caron, S. Petersenn, A. Houchard, C. Sert, J.S. Bevan, P.S. Group, Glucose and lipid levels with lanreotide autogel 120 mg in treatment-naive patients with acromegaly: data from the PRIMARYS study. Clin. Endocrinol. 86(4), 541–551 (2017)CrossRef
113.
J.A. Beentjes, A. van Tol, W.J. Sluiter, R.P. Dullaart, Low plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone deficient and acromegalic men: role in altered high density lipoproteins. Atherosclerosis 153(2), 491–498 (2000)CrossRefPubMed
114.
Y. Bonde, O. Breuer, D. Lutjohann, S. Sjoberg, B. Angelin, M. Rudling, Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans. J. Lipid Res. 55(11), 2408–2415 (2014)CrossRefPubMedPubMedCentral
115.
L. Persson, P. Henriksson, E. Westerlund, O. Hovatta, B. Angelin, M. Rudling, Endogenous estrogens lower plasma PCSK9 and LDL cholesterol but not Lp(a) or bile acid synthesis in women. Arterioscler. Thromb. Vasc. Biol. 32(3), 810–814 (2012)CrossRefPubMed
116.
P. Costet, B. Cariou, G. Lambert, F. Lalanne, B. Lardeux, A.L. Jarnoux, A. Grefhorst, B. Staels, M. Krempf, Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J. Biol. Chem. 281(10), 6211–6218 (2006)CrossRefPubMed
117.
B. Cariou, C. Langhi, M. Le Bras, M. Bortolotti, K.A. Le, F. Theytaz, C. Le May, B. Guyomarc’h-Delasalle, Y. Zair, R. Kreis, C. Boesch, M. Krempf, L. Tappy, P. Costet, Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets. Nutr. Metab. 10(1), 4 (2013)CrossRef
118.
K.R. Feingold, A.H. Moser, J.K. Shigenaga, S.M. Patzek, C. Grunfeld, Inflammation stimulates the expression of PCSK9. Biochem. Biophys. Res. Commun. 374(2), 341–344 (2008)CrossRefPubMedPubMedCentral
119.
S.G. Lakoski, T.A. Lagace, J.C. Cohen, J.D. Horton, H.H. Hobbs, Genetic and metabolic determinants of plasma PCSK9 levels. J. Clin. Endocrinol. Metab. 94(7), 2537–2543 (2009)CrossRefPubMedPubMedCentral
120.
Y. Matsuda, H. Kawate, C. Matsuzaki, R. Sakamoto, I. Abe, K. Shibue, M. Kohno, M. Adachi, K. Ohnaka, M. Nomura, R. Takayanagi, Reduced arterial stiffness in patients with acromegaly: non-invasive assessment by the cardio-ankle vascular index (CAVI). Endocr. J. 60(1), 29–36 (2013)CrossRefPubMed
121.
C.L. Ronchi, S. Corbetta, V. Cappiello, P.S. Morpurgo, C. Giavoli, P. Beck-Peccoz, M. Arosio, A. Spada, Circulating adiponectin levels and cardiovascular risk factors in acromegalic patients. Eur. J. Endocrinol. 150(5), 663–669 (2004)CrossRefPubMed
122.
A. Colao, R. Pivonello, L.F. Grasso, R.S. Auriemma, M. Galdiero, S. Savastano, G. Lombardi, Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study. Eur. J. Endocrinol. 165(5), 713–721 (2011)CrossRefPubMed
123.
K.S. Lam, A. Xu, K.C. Tan, L.C. Wong, S.C. Tiu, S. Tam, Serum adiponectin is reduced in acromegaly and normalized after correction of growth hormone excess. J. Clin. Endocrinol. Metab. 89(11), 5448–5453 (2004)CrossRefPubMed
124.
P. Wiesli, R. Bernays, M. Brandle, C. Zwimpfer, H. Seiler, J. Zapf, G. A Spinas, C: Schmid, Effect of pituitary surgery in patients with acromegaly on adiponectin serum concentrations and alanine aminotransferase activity. Clin. Chim. Acta 352(1-2), 175–181 (2005)CrossRefPubMed
125.
N. Sucunza, M.J. Barahona, E. Resmini, J.M. Fernandez-Real, W. Ricart, J. Farrerons, J. Rodriguez Espinosa, A.M. Marin, T. Puig, S.M. Webb, A link between bone mineral density and serum adiponectin and visfatin levels in acromegaly. J. Clin. Endocrinol. Metab. 94(10), 3889–3896 (2009)CrossRefPubMed
126.
J.V. Silha, M. Krsek, V. Hana, J. Marek, J. Jezkova, V. Weiss, L.J. Murphy, Perturbations in adiponectin, leptin and resistin levels in acromegaly: lack of correlation with insulin resistance. Clin. Endocrinol. 58(6), 736–742 (2003)CrossRef
127.
L. Boero, L. Cuniberti, N. Magnani, M. Manavela, V. Yapur, M. Bustos, L. Gomez Rosso, T. Merono, L. Marziali, L. Viale, P. Evelson, G. Negri, F. Brites, Increased oxidized low density lipoprotein associated with high ceruloplasmin activity in patients with active acromegaly. Clin. Endocrinol. 72(5), 654–660 (2010)CrossRef
128.
K.K. Miller, T. Wexler, P. Fazeli, L. Gunnell, G.J. Graham, C. Beauregard, L. Hemphill, L. Nachtigall, J. Loeffler, B. Swearingen, B.M. Biller, A. Klibanski, Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement. J. Clin. Endocrinol. Metab. 95(2), 567–577 (2010)CrossRefPubMedPubMedCentral
129.
G. Brevetti, P. Marzullo, A. Silvestro, R. Pivonello, G. Oliva, C. di Somma, G. Lombardi, A. Colao, Early vascular alterations in acromegaly. J. Clin. Endocrinol. Metab. 87(7), 3174–3179 (2002)CrossRefPubMed
130.
Y. Winhofer, P. Wolf, M. Krssak, S. Wolfsberger, A. Tura, G. Pacini, A. Gessl, W. Raber, I.J. Kukurova, A. Kautzky-Willer, E. Knosp, S. Trattnig, M. Krebs, A. Luger, No evidence of ectopic lipid accumulation in the pathophysiology of the acromegalic cardiomyopathy. J. Clin. Endocrinol. Metab. 99(11), 4299–4306 (2014)CrossRefPubMed
131.
A.N. Paisley, M. Banerjee, M. Rezai, R.E. Schofield, S. Balakrishnannair, A. Herbert, J.A. Lawrance, P.J. Trainer, J.K. Cruickshank, Changes in arterial stiffness but not carotid intimal thickness in acromegaly. J. Clin. Endocrinol. Metab. 96(5), 1486–1492 (2011)CrossRefPubMed
132.
A.K. Annamalai, A. Webb, N. Kandasamy, M. Elkhawad, S. Moir, F. Khan, K. Maki-Petaja, E.L. Gayton, C.H. Strey, S. O’Toole, S. Ariyaratnam, D.J. Halsall, A.N. Chaudhry, L. Berman, D.J. Scoffings, N.M. Antoun, D.P. Dutka, I.B. Wilkinson, J.M. Shneerson, J.D. Pickard, H.L. Simpson, M. Gurnell, A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. J. Clin. Endocrinol. Metab. 98(3), 1040–1050 (2013)CrossRefPubMed
133.
C.M. Dos Santos Silva, G.A. Lima, I.C. Volschan, I. Gottlieb, L. Kasuki, L.V. Neto, M.R. Gadelha, Low risk of coronary artery disease in patients with acromegaly. Endocrine 50(3), 749–755 (2015)CrossRefPubMed
134.
J. Gibney, T. Wolthers, M.G. Burt, K.C. Leung, A.M. Umpleby, K.K. Ho, Protein metabolism in acromegaly: differential effects of short- and long-term treatment. J. Clin. Endocrinol. Metab. 92(4), 1479–1484 (2007)CrossRefPubMed
135.
M. Bolanowski, A. Milewicz, B. Bidzinska, D. Jedrzejuk, J. Daroszewski, E. Mikulski, Serum leptin levels in acromegaly--a significant role for adipose tissue and fasting insulin/glucose ratio. Med. Sci. Monit. 8(10), CR685–689 (2002)PubMed
136.
M. Madeira, L.V. Neto, G.A. de Lima, R.O. Moreira, L.M. de Mendonca, M.R. Gadelha, M.L. Farias, Effects of GH-IGF-I excess and gonadal status on bone mineral density and body composition in patients with acromegaly. Osteoporos. Int. 21(12), 2019–2025 (2010)CrossRefPubMed
137.
T.B. Hansen, J. Gram, P. Bjerre, C. Hagen, J. Bollerslev, Body composition in active acromegaly during treatment with octreotide: a double-blind, placebo-controlled cross-over study. Clin. Endocrinol. 41(3), 323–329 (1994)CrossRef
138.
G.V. Frajese, N.F. Taylor, P.J. Jenkins, G.M. Besser, J.P. Monson, Modulation of cortisol metabolism during treatment of acromegaly is independent of body composition and insulin sensitivity. Horm. Res. 61(5), 246–251 (2004)PubMed
139.
M. Tzanela, D.A. Vassiliadi, N. Gavalas, A. Szabo, E. Margelou, A. Valatsou, C. Vassilopoulos, Glucose homeostasis in patients with acromegaly treated with surgery or somatostatin analogues. Clin. Endocrinol. 75(1), 96–102 (2011)CrossRef
140.
P.U. Freda, C.M. Reyes, I.M. Conwell, R.E. Sundeen, S.L. Wardlaw, Serum ghrelin levels in acromegaly: effects of surgical and long-acting octreotide therapy. J. Clin. Endocrinol. Metab. 88(5), 2037–2044 (2003)CrossRefPubMed
Metadata
Title
Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature
Authors
Claire Briet
Mirela Diana Ilie
Emmanuelle Kuhn
Luigi Maione
Sylvie Brailly-Tabard
Sylvie Salenave
Bertrand Cariou
Philippe Chanson
Publication date
01-02-2019
Publisher
Springer US
Published in
Endocrine / Issue 2/2019
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-018-1797-8

Other articles of this Issue 2/2019

Endocrine 2/2019 Go to the issue

Endocrine Surgery

Clinical characteristics and surgical outcome in USP8-mutated human adrenocorticotropic hormone-secreting pituitary adenomas

Original Article

Prevalence and reproductive manifestations of macroprolactinemia

Original Article

Diagnostic value of ultrasonography and TI-201/Tc-99m dual scintigraphy in differentiating between benign and malignant thyroid nodules

Original Article

Anti-Müllerian hormone serum levels in systemic lupus erythematosus patients: Influence of the disease severity and therapy on the ovarian reserve

Original Article

Risk factors for local recurrence following lateral neck dissection for papillary thyroid carcinoma

Endocrine Surgery

Intraoperative unfolding and postoperative pruning of the pituitary gland after transsphenoidal surgery for pituitary adenoma: A volumetric and endocrinological evaluation
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits